Barinthus BiotherapeuticsSTU:2AB 14 Debt-to-Equity is 0.17 as of Mar. 2026, which is 183% above its 10-year median of 0.06. GuruFocus rates STU:2AB with a GF Score™ of 14/100 and a GF Value™ of €0.94. The stock has 1 warning sign investors should review. Among 965 Biotechnology companies, Barinthus Biotherapeutics ranks worse than 50.78% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Barinthus Biotherapeutics's Debt-to-Equity or its related term are showing as below:
STU:2AB'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.24 Med: 0.06 Max: 0.17
Current: 0.17
During the past 7 years, the highest Debt-to-Equity Ratio of Barinthus Biotherapeutics was 0.17. The lowest was -1.24. And the median was 0.06.
STU:2AB's Debt-to-Equity is ranked worse than 50.78% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs STU:2AB: 0.17
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Barinthus Biotherapeutics Debt-to-Equity Related Terms
Barinthus Biotherapeutics Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2AB vs VTGN, PSTV, PVCT: Debt-to-Equity Comparison
For the Biotechnology subindustry, Barinthus Biotherapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics (STU:2AB) has a Debt-to-Equity of 0.17 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Barinthus Biotherapeutics and its competitors. This is 183% above median its historical median of 0.06. According to the industry distribution chart, Barinthus Biotherapeutics ranks #490 out of 965 companies in the Biotechnology industry, placing it in the top 50.8%.
Is Barinthus Biotherapeutics' Debt-to-Equity too high?
Barinthus Biotherapeutics' current Debt-to-Equity of 0.17 is 183% above median its 10-year median of 0.06. The Biotechnology industry median Debt-to-Equity is 0.16. Barinthus Biotherapeutics' value of 0.17 is 6.3% above this industry median. Based on the distribution chart, Barinthus Biotherapeutics ranks #490 out of 965 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Debt-to-Equity compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #490 out of 965 companies for Debt-to-Equity. This places Barinthus Biotherapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Barinthus Biotherapeutics' value of 0.17 is 6.3% above this benchmark. While the company's 10-year median is 0.06 vs. the industry median of 0.16, Barinthus Biotherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Barinthus Biotherapeutics's current Debt-to-Equity of 0.17 is 6.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Barinthus Biotherapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Barinthus Biotherapeutics's current Debt-to-Equity is 0.17, which is 183% above median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current Debt-to-Equity of 0.17. The stock's GF Value™ is €0.94, compared to a current price of €0.52 — trading 44.7% below its estimated fair value. The current Debt-to-Equity is 0.17, which is 183% above median its 10-year median of 0.06 and 6.3% above the Biotechnology industry median of 0.16. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current Debt-to-Equity is 0.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of €0.52 is trading 44.7% below its estimated GF Value™ of €0.94.
Key valuation signals for STU:2AB:
Debt-to-Equity: 0.17 (183% above median its 10-year median of 0.06)
GF Value™: €0.94 vs. price of €0.52 (44.7% below fair value)
Industry Position: 6.3% above the Biotechnology median (#490 of 965)
No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score
Get the complete analysis for STU:2AB
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2AB has been successfully added to your 
